Coordinator: Univ.- Prof. Dr. rer. nat. Joachim Jankowski
Managing Director: Heidi Noels, PhD
CArdioREnal SYndrome ANalysis
Towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease
We will train young scientists to combat cardiovascular burden in chronic kidney disease by providing them with excellent scientific, technological and complementary skills to generate innovative insights in the pathology of the cardiorenal syndrome, and translate these into innovative clinical products. Ultimately, this will improve diagnosis as well as therapy of the cardiorenal syndrome and reduce the socio-economic burden of this disease.
Our consortium will organize a multidisciplinary training programme for early-stage researchers (ESRs) to enable them translating knowledge and ideas in the field of the cardiorenal syndrome into innovative research and products. This multi-disciplinary training programme will be embedded in an already established cooperation of academic and non-academic partners. As part of their scientific training, the recruited ESRs will (Fig. 1):
Identify by proteomics/peptidomics analyses to reveal candidates for diagnosis, prediction and treatment of the cardiorenal syndrome.
Generate a using bioinformatics, to assess the value of biomarker candidates in diagnostic and predictive signatures, and reveal key candidates for biomarkers and targets.
Study , the role of biomarker/target candidates and novel therapeutic strategies, to reveal novel diagnostic and therapeutic options.
Patients with chronic kidney disease (CKD) exhibit a massively increased risk for cardiovascular events: 50% of patients with CKD stage 4-5 suffer from cardiovascular disease (CVD) , and cardiovascular mortality accounts for ~40-50% of all deaths in patients with CKD stage 4 as well as patients with end-stage renal disease, compared with 26% in controls with normal kidney function . With 10-13% of people presenting CKD and CVD accounting for ~9% of total health care costs, the socio-economic burden of this cardiovascular-renal pathology, referred to as the cardiorenal syndrome, is extremely high.
Recent studies have revealed that CKD itself is an independent risk factor for cardiovascular events . This may explain in part why traditional strategies to improve cardiovascular outcome have largely failed in the context of CKD . Also, this emphasizes the need to identify CKD-specific pathology, biomarkers and targets for CVD, in order to reduce the increased cardiovascular mortality in CKD patients through novel diagnostic and therapeutic strategies.
1.Stevens et al. Kidney Int 2007; 2.Thompson et al. J Am Soc Nephrol 2015; 3.Drey et al. Am J Kidney Dis 2003; 4.Ortiz et al. Lancet 2014; 5.Tonelli et al. Lancet 2012.
The cardiorenal syndrome forms a major socio-economic problem and current diagnostic and therapeutic possibilities are limited and not able to combat the cardiorenal syndrome. CaReSyAn integrates tailored innovations to address these needs.
CaReSyAn will train the next generation of high-potential translational researchers in the field of the cardiorenal syndrome within an existing network of excellent research groups across Europe, ultimately leading to a reduction in cardiovascular mortality in CKD patients through novel diagnostic and therapeutic strategies.
By providing excellent training of young scientists, CaReSyAn strives to improve the diagnosis as well as therapy of the cardiorenal syndrome and reduce the socio-economic burden of this disease.